# CVS Health Corporation (CVS)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-12  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/CVS/primer

## Business Model

---
ticker: CVS
step: 01
generated: 2026-05-12
source: quick-research
---

### CVS Health Corporation (CVS) — Business Overview

#### Business Description
CVS Health is the world's largest integrated healthcare company by revenue, operating across three vertically connected segments: **Aetna health insurance** (~$130B+ revenue), **CVS Caremark pharmacy benefits manager** (~$185B+), and **CVS Pharmacy retail + Oak Street + Signify Health** ($90B+ retail health). The company is mid-turnaround under **CEO David Joyner** (took over October 2024 replacing Karen Lynch). Focus: (1) Aetna Medicare Advantage turnaround (medical loss ratio improving from 87.3% Q1 2024 to 84.6% Q1 2026); (2) $2B+ cost-cutting program; (3) closing ~900 underperforming pharmacy stores; (4) revamping Oak Street Health primary-care strategy after a $5.7B impairment charge.

#### Revenue Model
Three reportable segments:
- **Health Care Benefits** (Aetna) — ~$130B revenue; commercial + Medicare + Medicaid + dental/vision/behavioral health. Q1 2026 medical loss ratio improved to 84.6%.
- **Health Services** — ~$190B revenue; CVS Caremark PBM + Oak Street Health (primary care for Medicare seniors) + Signify Health (in-home assessments) + MinuteClinic.
- **Pharmacy and Consumer Wellness** — ~$130B revenue; CVS retail pharmacies (~9,000 stores after closures); front-of-store retail; long-term care pharmacy.

Revenue mix is the largest in healthcare; intersegment eliminations are significant (~$80B+) as CVS Caremark fills prescriptions for Aetna members at CVS Pharmacy stores.

#### Products & Services
- **Aetna Health Plans**: Commercial group employer, individual ACA exchanges, Medicare Advantage (top-tier 4+ Star ratings for 2026), Medicaid managed care, Medicare Supplemental.
- **CVS Caremark PBM**: Drug pricing negotiation, formulary management, specialty pharmacy (CVS Specialty), pharmacy network management; serves Aetna + 3rd-party plans.
- **Oak Street Health**: Primary care for Medicare/Medicaid; ~225+ centers (being restructured post-impairment).
- **Signify Health**: In-home health assessments for Medicare Advantage plans (acquired 2023).
- **CVS Pharmacy retail**: ~9,000 stores (down from ~9,700 pre-closures); prescriptions, OTC, front-of-store retail.
- **MinuteClinic**: Walk-in clinics inside CVS stores; basic primary care.
- **CVS Specialty**: Specialty drug fulfillment.

#### Customer Base & Go-to-Market
- **Aetna members**: ~26M+ medical members across commercial + Medicare + Medicaid.
- **Caremark PBM members**: ~107M+ lives covered.
- **CVS Pharmacy customers**: ~5M+ daily customers across 9,000+ stores.
- **Oak Street + Signify Health patients**: Medicare/Medicaid seniors and at-risk populations.
- **Employers**: Self-funded employer customers for both Caremark PBM and Aetna ASO plans.

Distribution: Direct retail (CVS Pharmacy stores), online (cvs.com), B2B sales force (Aetna + Caremark for employers + government), in-home (Signify), value-based care centers (Oak Street).

#### Competitive Position
CVS Health competes across multiple healthcare verticals:

**Health Insurance (Aetna):**
- UnitedHealth (UnitedHealthcare) — Larger; better-positioned MA leader.
- Humana — Pure-play MA leader.
- Elevance (Anthem BCBS) — Diversified BCBS franchise.
- Cigna — Smaller competitor, plus PBM via Express Scripts.

**PBM (Caremark):**
- Express Scripts (Cigna) — Direct competitor.
- OptumRx (UnitedHealth) — Direct competitor.
- Together these "Big 3" PBMs cover ~80% of US prescription volume.

**Retail Pharmacy:**
- Walgreens — Direct competitor; in severe distress.
- Amazon Pharmacy — Emerging digital-first threat.
- Walmart + Costco pharmacy — Lower-priced models.
- Independent / supermarket pharmacies — Fragmented.

**Primary Care (Oak Street):**
- UnitedHealth Optum (much larger primary care footprint).
- Privia, ChenMed, Walmart Health, Amazon Clinic.

Structural moats: (1) **vertical integration** — Aetna + Caremark + CVS Pharmacy + Oak Street create cross-segment economics no competitor matches at scale; (2) **member captive flow** — Aetna members fill prescriptions at CVS Pharmacy via Caremark; (3) **MinuteClinic + Signify Health primary care reach**.

Active risks: (1) PBM regulation pressure on rebate retention; (2) Medicare Advantage rate-cycle pressure from CMS; (3) Walgreens distress could create competitive opportunity OR price war; (4) Amazon Pharmacy + transparent pricing competition.

#### Key Facts
- Founded: 1963 (as Consumer Value Stores)
- Headquarters: Woonsocket, Rhode Island
- Employees: ~300,000+
- Exchange: NYSE
- Sector / Industry: Health Care / Healthcare Plans + Retail Pharmacy
- Market Cap: ~$95B
- FY2024 Revenue: $372.8B
- FY2025 Revenue: ~$385B (estimated based on guide)
- FY2026 Revenue Guide: $400B+ (raised to $405B+ after Q1 2026)
- FY2026 Adjusted EPS Guide: $7.30–7.50 (raised from $7.00–7.20)
- Aetna Medical Members: ~26M+
- CVS Caremark PBM Lives: ~107M
- CVS Pharmacy Stores: ~9,000 (after closing ~900)
- CEO: David Joyner (since October 2024)
- Dividend Yield: ~4.5%
- Major Recent Events: Oak Street Health $5.7B impairment Q3 2025; ongoing cost-cutting $2B+ program; pharmacy closures

## Financial Snapshot

---
ticker: CVS
step: 04
generated: 2026-05-12
source: quick-research
---

### CVS Health Corporation (CVS) — Financial Snapshot

#### Income Statement Summary

| Metric | FY2023 | FY2024 | FY2025 | YoY (FY25) |
|--------|--------|--------|--------|------------|
| Total Revenue | $357.8B | $372.8B | ~$390B | +4–5% |
| GAAP EPS | $6.47 | $3.40 (impairment-impacted) | ~$5.50 (rebound) | recovery |
| Adjusted EPS | $8.74 | $5.94 | ~$6.50 | recovering |

#### Q1 2026 Beat + Raised Guidance

| Metric | Q1 2026 |
|--------|---------|
| Revenue | $100.4B (+6.2% YoY) |
| GAAP EPS | $2.30 (vs. $1.41) |
| Adjusted EPS | $2.57 (vs. $2.25) |
| Aetna Medical Loss Ratio | 84.6% (vs. 87.3% prior year) |
| Operating Cash Flow | $4.2B |

#### FY2026 Raised Guidance (post Q1)

| Metric | 2026 Guide |
|--------|-----------|
| Revenue | At least $405B (raised from $400B) |
| Adjusted EPS | $7.30–7.50 (raised from $7.00–7.20) |
| GAAP EPS | $6.24–6.44 |
| Operating Cash Flow | At least $9.5B |
| Capital Returned to Shareholders | Quarterly dividends maintained |

#### Cash Flow & Capital Allocation (FY2025)

| Metric | Value |
|--------|-------|
| Operating Cash Flow | ~$8B (constrained by working capital) |
| Capital Expenditures | ~$3.5B |
| Free Cash Flow | ~$4.5B |
| Quarterly Dividend | $0.665 |
| Annual Dividend | $2.66 |
| Dividend Yield | ~4.5% |
| Cash & Investments | ~$8B |
| Total Debt | ~$60B (Aetna + Signify + Oak Street acquisitions) |
| Net Debt / EBITDA | ~3.0x |

#### Segment Performance Trends

| Segment | FY2025 Trends |
|---------|--------------|
| Health Care Benefits (Aetna) | MLR improving 84.6% (Q1 26) vs. 87.3% (Q1 25); Medicare Advantage stars top-tier for 2026 |
| Health Services (Caremark + Oak Street + Signify) | Caremark stable; Oak Street restructured post $5.7B impairment Q3 25 |
| Pharmacy & Consumer Wellness | Pharmacy script volume up; ~900 underperforming stores closed |

#### Key Ratios (approximate)
- P/E: ~10x (FY26E EPS midpoint) | EV/EBITDA: ~9x | FCF Yield: ~5%
- Revenue Growth (FY25): +4–5%
- Aetna MLR (Q1 26): 84.6% (vs. 87.3% Q1 25)
- Dividend Yield: ~4.5%
- Net Debt / EBITDA: ~3.0x

#### Growth Profile
2025 was the **trough year for Aetna** — Medicare Advantage cost pressures + Inflation Reduction Act + medical-cost inflation drove FY24 GAAP EPS down to $3.40 ($5.7B Oak Street impairment in Q3 2025). FY25 began the recovery; Q1 2026 confirmed the turnaround:
- Aetna MLR improved 270 bps YoY to 84.6%
- Aetna 2026 Medicare Advantage star ratings top-tier among national payers
- Caremark PBM stable
- Pharmacy + consumer wellness benefiting from closure of underperforming stores ($2B+ cost-cut program)
- FY26 EPS guide raised from $7.00–7.20 to $7.30–7.50

The defining 2026 narrative: **Aetna MA recovery + cost discipline + revamped Oak Street strategy**.

#### Forward Estimates
FY2026 Guide (raised post Q1):
- Revenue: ≥$405B
- Adjusted EPS: $7.30–7.50 (~$2 above FY25)
- FCF: ≥$9.5B operating cash flow

Bull case: Aetna MA returns to historical 86%+ MLR profitability (FY26-27); Caremark PBM regulatory pressure manageable; pharmacy closure benefits flow through margin; EPS reaches $9+ by FY28; multiple expands to 13x. Bear case: Medicare Advantage rate cycle remains unfavorable (CMS rate cuts); PBM rebate retention regulation passes; pharmacy front-store retail weakness; EPS stuck at $7. Consensus targets ~$90–105 vs. trading ~$74–84 (~15–30% implied upside).

## Recent Catalysts

---
ticker: CVS
step: 12
generated: 2026-05-12
source: quick-research
---

### CVS Health Corporation (CVS) — Investment Catalysts & Risks

#### Bull Case Drivers

1. **Aetna Medicare Advantage turnaround — MLR improving 270 bps to 84.6%** — Q1 2026 confirmed Aetna's recovery story. MLR of 84.6% (vs. 87.3% prior year) signals materially improved underwriting; FY26 EPS guide raised from $7.00–7.20 to $7.30–7.50.
2. **Aetna 2026 Medicare Advantage Stars top-tier** — Even with CMS tightening cut points, Aetna maintained top-tier 4+ Star ratings among national payers. Critical to MA bonus payments + member retention.
3. **$2B+ cost-cutting program executing** — Closed ~900 underperforming pharmacy stores; corporate cost reduction; revamping Oak Street primary care after $5.7B impairment. CEO Joyner driving operational discipline.
4. **Q1 2026 revenue $100B + EPS $2.57** — Solid operational momentum; revenue +6.2%; raised guidance confirms execution.
5. **Vertical integration moat** — Aetna + Caremark + CVS Pharmacy create cross-segment economics no competitor matches (UNH being the only comparable). Aetna members fill prescriptions at CVS via Caremark.
6. **4.5% dividend yield** — Among the highest in mega-cap healthcare; supports income investor demand.
7. **Walgreens distress creates opportunity** — Walgreens going private + cutting stores reduces competitive intensity in retail pharmacy.
8. **Caremark PBM stability** — Despite political pressure, Big 3 PBM oligopoly is structurally entrenched.

#### Bear Case Risks

1. **PBM regulation tail risk** — Bipartisan congressional pressure on PBM rebate retention; potential structural reform could reduce Caremark profitability by 20-30%. Multi-year tail risk.
2. **Medicare Advantage rate cycle pressure** — CMS proposed essentially flat 2027 MA payments + IRA effects + medical cost inflation continue to compress MA economics. Even with improved Aetna MLR, the rate cycle is the binding constraint.
3. **Oak Street Health $5.7B impairment + revamp execution** — Primary care strategy materially impaired; future returns uncertain. Oak Street is consuming capital without clear ROIC.
4. **Pharmacy retail closures continue** — Closing stores is necessary but reflects underlying retail pharmacy challenge; e-commerce + Amazon Pharmacy + Walmart pressure on front-of-store retail.
5. **High debt ($60B; ~3x net debt/EBITDA)** — Constrains M&A flexibility; sensitive to credit conditions.
6. **Amazon Pharmacy + transparent pricing competition** — Long-term threat to retail pharmacy margins.
7. **Adverse drug pricing legislation** — Mark Cuban Cost Plus pharmacy + transparent pricing movement creates structural pressure on PBM economics.
8. **Operational complexity from acquisitions** — Aetna ($69B), Signify ($8B), Oak Street ($10.6B) — integration challenges persist.

#### Upcoming Events
- **Q2 2026 earnings (early August 2026)**: Mid-year guide check + Aetna MLR trajectory.
- **Q3 2026 earnings (early November 2026)**: Medicare Advantage open enrollment results.
- **CMS 2027 MA rate finalization (April 2027)**: Multi-year impact on Aetna profitability.
- **Medicare Advantage open enrollment (October–December 2026)**: 2027 plan year member additions.
- **PBM regulation Senate/House votes**: Ongoing through 2026–27 Congress.
- **Oak Street restructuring milestones**: Quarterly progress on revamped strategy.
- **Pharmacy closure completion**: ~900 stores closing through 2026.

#### Analyst Sentiment
Consensus rating is **Hold / Mixed** (~45% Buy, 50% Hold, 5% Sell). Price targets cluster $90–105 vs. trading ~$74–84 (~15–30% implied upside). Bull case targets ~$120 on Aetna MA recovery + Caremark stability; bear case ~$60 on MA rate cycle + PBM regulation. Morgan Stanley, BofA, Wells Fargo Buy/Overweight on turnaround thesis; UBS at Neutral; Goldman at Buy with target $105; Cowen at Buy.

#### Research Date
Generated: 2026-05-12

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/cvs
- Full research API: GET /api/v1/research/CVS/memo
- Coverage universe: /stocks